



Determination of the absolute configuration of the diterpene tonantzitlolone B

Torsten Busch, Hannah Schuster, Andreas Kirschning*

Institut für Organische Chemie and Zentrum für Biomolekulare Wirkstoffe (BMWZ), Leibniz Universität Hannover, Schneiderberg 1B, D-30167 Hannover, Germany

ARTICLE INFO

Article history:

Received 25 April 2008

Revised 20 June 2008

Accepted 24 June 2008

Available online 28 June 2008

Keywords:

Diterpenes

Natural products

Total synthesis

Semisynthesis

Structure elucidation

ABSTRACT

In this work synthetic and semi-synthetic studies toward the antitumor active natural product tonantzitlolone B are described, starting with an advanced intermediate obtained from the total synthesis of tonantzitlolone and a natural sample of this compound, respectively. The unknown absolute configuration of the stereogenic center in the side chain was elucidated to be (*R*).

© 2008 Elsevier Ltd. All rights reserved.

Tonantzitlolone (**1**) and Tonantzitlolone B (**2**) (Fig. 1) were isolated from the Mexican plant *Stillingia sanguinolentia*.¹ The roots and leaves of *S. sanguinolentia* have been used for the treatment of various medical purposes by the Mexican natives, and similar applications of *S. sylvatica* by Navajo and Creek Native Americans have been reported. Primary biological tests showed activity and selectivity of **1** and **2** against human kidney and breast cancer cell lines.

The total synthesis of (*ent*)-Tonantzitlolone (*ent*-**1**) was recently accomplished in our laboratories and established the depicted absolute configuration of the macrocycle.²

Since the absolute configuration of the side chain of Tonantzitlolone B (**2**) was still unknown and could not be determined spectroscopically, a synthetic approach toward **2** was pursued. Thus, we prepared the macrocycle **3** of naturally occurring Tonantzitlolone (**1**) according to the protocol described before for *ent*-**1** (Scheme 1).^{2,3} Building blocks **4**–**7** served to assemble dihydroxyketone **8** which was subjected to ring closing metathesis conditions.^{4,5} The resulting macrocycle **9** was further elaborated to tetraol **3** by a set of standard transformations.

At this point, the side chain of Tonantzitlolone B which had to be introduced was prepared (Scheme 2). The synthesis of both enantiomers **12a,b** started from methyl lactates **10a,b**. TBS-protection and subsequent methyl lithium addition at very low temperature delivered the protected (*R*)-configured 3-hydroxy-2-butanone which was transformed into the corresponding α,β -unsaturated ester **11a** by a Horner-Wadsworth-Emmons





Figure 1. Tonantzitlolone (**1**) and tonantzitlolone B (**2**).

olefination. The (*4S*)-enantiomer **11b** was prepared by a modified route via the Weinreb amide (amide formation, Grignard addition, protection, HWE). However, this synthesis turned out to be longer and gave lower yields. In the following steps, TBAF-mediated desilylation, saponification, and acetylation of the hydroxy group delivered the (*R*)- and (*S*)-configured acids **12a,b**, respectively.


Separate coupling of **12a** and **12b** with the macrocycle **3** was achieved under conditions previously established for the synthesis of Tonantzitlolone **1**. However, a large excess of the carboxylic acid **12** and diisopropylcarbodiimide (DIC) in the presence of 4-DMAP afforded a complex mixture of coupling products for both carboxylic acids **12a,b** (Scheme 3). After oxidation, the resulting products could not be separated by HPLC. Samples containing enriched isomers were analyzed, and from the ¹H NMR and the ¹H,¹H-COSY spectra it could unequivocally be concluded that all major products resulted from esterification at C-4.⁶ Additionally, a remarkable correlation between the ¹H NMR spectrum of authentic Tonantzitlolone B (**2**) and a minor product in the ¹H NMR spectrum of one

* Corresponding author.


E-mail address: andreas.kirschning@oci.uni-hannover.de (A. Kirschning).



Scheme 1. Synthesis of macrocycle **3** according to Ref. 2.




Scheme 2. Preparation of side chain **12** [only (*R*)-series shown]. Reagents and conditions: (a) DMF, imidazole, TBSCl, rt, 19 h; (b) THF, MeLi, -105°C , 45 min, then TMSCl, -105°C , 20 min, then HCl, rt, 1 h, >99% (2 steps); (c) $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{CO}_2\text{Et}$, NaH, THF, rt, 22 h, 48%; (d) TBAF $3\text{H}_2\text{O}$, THF, rt; (e) LiOH, MeOH/ H_2O 1:2, rt, 3 h; (f) Ac_2O , NEt_3 , 4-DMAP, rt, 1.5 h, 36% (3 steps).



Scheme 3. Attempts of C8-esterification of **3**. Reagents and conditions: (a) 15 equiv **12a,b**, 15 equiv DIC, DMAP, CH_2Cl_2 , rt, 4–5 h; (b) TPAP, NMO, CH_2Cl_2 , rt, 0.5–1 h; for **12a**: 44% (1:1 ratio of both esters formed); for **12b**: 57% (1.2:1).

fraction [formed after esterification with (*R*)-configured **12a**] was encountered. At this point we were unable to purify and fully characterize the expected (*R*)-isomer.

In order to finally prove the (*4R*)-configuration in the side chain, we turned our attention to a semi-synthetic strategy using authentic Tonantzilolone (**1**) as the starting point. While simple removal of the methyl senecioate side chain by transesterification or saponification turned out to be impossible, treatment with 7 equiv DIBAL led to reduction of the keto group at C-4 and to some extent to simultaneous cleavage of the ester. However, when only 1 equiv DIBAL was employed the selective reduction of the C-4 carbonyl group could be achieved to yield the epimeric alcohols which were separated by chromatography. Silylation of each alcohol yielded Tonantzilolone derivatives **13a,b** (Scheme 4). Reductive removal of the methyl senecioate side chain in **13b** with 5 equiv DIBAL delivered small amounts of the mono-protected compound **14**. When epimeric **13a** was subjected to these conditions, only traces



Scheme 4. Semisynthesis of Tonantzilolone B (**2**) from **1**. Reagents and conditions: (a) 1 equiv DIBAL, CH_2Cl_2 , -78°C to 0°C , 30 min, 27% for α -diastereoisomer, 55% for β -diastereoisomer; (b) TBSOTf, 2,6-lutidine, CH_2Cl_2 , rt, 45 min, 66% for **13a** and 71% for **13b**; (c) 5 equiv DIBAL, CH_2Cl_2 , -78°C to 0°C , 5 h, 22%; (d) 15 equiv **12a**, 15 equiv DIC, DMAP, THF, 40°C , 5 d; (e) TBAF $3\text{H}_2\text{O}$, THF, rt, 17 h; (f) TPAP, NMO, CH_2Cl_2 , 4 Å MS, rt, 45 min, 25% (3 steps).

of the isomeric analogue of **14** were detected. Isolation of **16** clearly revealed the principal problem of chemoselectivity associated with this step which explains the low isolated yield for **14**.

Esterification with the (*R*)-configured acid **12a** was only achieved when a large excess of acylating reagents was added portionwise over 6 h. Otherwise, we encountered substantial acylation of one diimide nitrogen atom of the DIC reagent. In the following the acylation product **15** was desilylated and selectively oxidized at C-4. The ^1H and ^{13}C NMR spectroscopic data as well as CD spectra of the resulting Tonantzilolone derivative were compared with those of authentic Tonantzilolone B (**2**),⁷ and confirmed the depicted configuration as being the natural one (see supporting data).

In summary, we determined the absolute configuration of the ester side chain of Tonantzilolone B utilizing two alternative synthetic strategies.

Acknowledgements

The work was funded by a graduate scholarship for T.B. provided by the Stiftung Stipendien-Fonds des Verbandes der Chemischen Industrie. We thank AnalytiCon Discovery GmbH (Potsdam, Germany) for providing a sample of authentic Tonantzilolone B.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2008.06.105.

References and notes

- Dräger, G.; Dominguez, X. A.; Sanchez, H. V.; Gomez Lopez, E. G.; Kunst, E.; Tschritzis, F.; Jeske, F.; Jakupovic, J.; Kirschning, A. *Eur. J. Org. Chem.* **2007**, 5020–5026.

2. (a) Wittenberg, R.; Monenschein, H.; Dräger, G.; Beier, C.; Jas, G.; Kirschning, A. *Tetrahedron Lett.* **2004**, *45*, 4457–4460; (b) Jasper, C.; Wittenberg, R.; Quitschalle, M.; Jakupovic, J.; Kirschning, A. *Org. Lett.* **2005**, *7*, 479–482; (c) Jasper, C.; Adibekian, A.; Busch, T.; Quitschalle, M.; Wittenberg, R.; Kirschning, A. *Chem. Eur. J.* **2006**, *12*, 8719–8734.
3. Busch, T.; Kirschning, A. *Nat. Prod. Rep.* **2008**, *25*, 318–341.
4. Gradillas, A.; Perez-Castells, J. *Angew. Chem.* **2006**, *118*, 6232–6247; *Angew. Chem., Int. Ed.* **2006**, *37*, 6086–6101.
5. Busch, T.; Ph. D. thesis, Leibniz Universität Hannover, 2007.
6. The observation that several C-4 esters are formed upon esterification/oxidation can be explained by α -epimerization at C-8 or C-10, respectively, of the ring opened acetal or by a non-selective oxidation with respect to the position (see also Ref. 2).
7. Selected analytical data of synthetic Tonantzitlolone B (**2**): ^1H NMR (CDCl_3 , 500 MHz, $\text{CHCl}_3 = 7.26$ ppm): $\delta_{\text{H}} = 5.93$ (br q, $J = 1.4$ Hz, 1H, 2'-H), 5.88 (d, $J = 15.0$ Hz, 1H, 1-H), 5.73 (s, 1H, 9-OH), 5.27 (br q, $J = 6.6$ Hz, 1H, 4'-H), 5.27 (dd, $J = 15.0, 9.7$ Hz, 1H, 2-H), 4.93 (d, $J = 2.6$ Hz, 1H, 8-H), 4.66 (dd, $J = 11.8, 2.9$ Hz, 1H, 5-H), 3.80 (dd, $J = 11.3, 5.1$ Hz, 1H, 14-H), 3.43 (d, $J = 6.4$ Hz, 1H, 10-H), 3.36 (dq, $J = 9.7, 7.0$ Hz, 1H, 3-H), 3.09 (d, $J = 6.6$ Hz, 1H, 10-OH), 2.46 (br dd, $J = 12.5, 7.5$ Hz, 1H, 12-H), 2.37–2.29 (m, 1H, 7-H), 2.16 (d, $J = 1.4$ Hz, 3H, 6'-H), 2.12 (s, 3H, COCH_3), 2.06–1.98 (m, 1H, 13-H), 1.88–1.82 (m, 1H, 6-H), 1.80 (ddd, $J = 5.1, 6.8, 11.5$ Hz, 1H, 13-H), 1.58–1.47 (m, 1H, 12-H), 1.40 (s, 3H, 18-H), 1.40–1.32 (m, 1H, 6-H), 1.38 (d, $J = 6.6$ Hz, 3H, 5'-H), 1.17 (s, 3H, 17-H), 1.16 (d, $J = 7.0$ Hz, 3H, 20-H), 0.91 (s, 3H, 16-H), 0.87 (d, $J = 7.0$ Hz, 3H 19-H) ppm; ^{13}C NMR (CDCl_3 , 125 MHz, $\text{CDCl}_3 = 77.16$ ppm): $\delta_{\text{C}} = 166.4$ (q, 1'-C), 157.8 (q, 3'-C), 140.2 (t, 1-C), 126.9 (t, 2-C), 115.2 (t, 2'-C), 89.0 (t, 14-C), 87.6 (q, 11-C), 78.3 (t, 10-C), 74.2 (t, 5-C), 73.9 (t, 4'-C), 73.8 (t, 8-C), 49.7 (t, 3-C), 38.9 (q, 15-C), 37.4 (s, 12-C), 29.2 (t, 7-C), 28.9 (s, 6-C), 28.3 (p, 18-C), 25.6 (p, 16-C), 25.2 (p, 17-C), 19.3 (p, 5'-C), 17.2 (p, 19-C), 16.2, 15.4 ($2 \times$ p, 20-C, 6'-C) ppm. Due to the small amount of synthetic material available the following carbon atoms could not be detected in the ^{13}C NMR spectrum: 211.4, 170.1, 97.2, 28.2 and 21.4 ppm.
- NMR data of authentic Tonantzitlolone B (**2**): ^1H NMR (CDCl_3 , 500 MHz, $\text{CDCl}_3 = 7.26$ ppm): $\delta_{\text{H}} = 5.93$ (br q, $J = 1.3$ Hz, 1H, 2'-H), 5.88 (d, $J = 15.3$ Hz, 1H, 1-H), 5.71 (s, 1H, 9-OH), 5.27 (br q, $J = 6.6$ Hz, 1H, 4'-H), 5.24 (dd, $J = 15.2, 9.6$ Hz, 1H, 2-H), 4.93 (d, $J = 2.8$ Hz, 1H, 8-H), 4.66 (dd, $J = 11.9, 2.8$ Hz, 1H, 5-H), 3.80 (dd, $J = 11.3, 5.2$ Hz, 1H, 14-H), 3.43 (d, $J = 6.6$ Hz, 1H, 10-H), 3.33 (dq, $J = 9.5, 6.8$ Hz, 1H, 3-H), 3.06 (d, $J = 6.6$ Hz, 1H, 10-OH), 2.43 (br dd, $J = 12.5, 7.4$ Hz, 1H, 12-H), 2.37–2.29 (m, 1H, 7-H), 2.13 (d, $J = 1.4$ Hz, 3H, 6'-H), 2.10 (s, 3H, COCH_3), 2.06–1.97 (m, 1H, 13-H), 1.87–1.82 (m, 1H, 6-H), 1.77 (ddd, $J = 5.3, 7.0, 12.0$ Hz, 1H, 13-H), 1.57–1.48 (m, 1H, 12-H), 1.37 (s, 3H, 18-H), 1.40–1.33 (m, 1H, 6-H), 1.35 (d, $J = 6.6$ Hz, 3H, 5'-H), 1.14 (s, 3H, 17-H), 1.13 (d, $J = 7.0$ Hz, 3H, 20-H), 0.91 (s, 3H, 16-H), 0.85 (d, $J = 7.0$ Hz, 3H 19-H) ppm; ^{13}C NMR (CDCl_3 , 125 MHz, $\text{CDCl}_3 = 77.16$ ppm): $\delta_{\text{C}} = 211.4$ (q, 4-C), 170.1 (q, COCH_3), 166.4 (q, 1'-C), 157.8 (q, 3'-C), 140.2 (t, 1-C), 126.9 (t, 2-C), 115.2 (t, 2'-C), 97.2 (q, 9-C), 89.0 (t, 14-C), 87.6 (q, 11-C), 78.3 (t, 10-C), 74.2 (t, 5-C), 73.9 (t, 4'-C), 73.8 (t, 8-C), 49.7 (t, 3-C), 38.9 (q, 15-C), 37.4 (s, 12-C), 29.2 (t, 7-C), 28.9 (s, 6-C), 28.3 (p, 18-C), 28.2 (s, 13-C), 25.6 (p, 16-C), 25.2 (p, 17-C), 21.4 (p, COCH_3), 19.3 (p, 5'-C), 17.2 (p, 19-C), 16.2, 15.4 ($2 \times$ p, 20-C, 6'-C) ppm.
- HRMS-ESI ($\text{C}_{28}\text{H}_{42}\text{O}_9$): calcd 545.2727 $[\text{M}+\text{Na}]^+$, found 545.2726.